The EPO published Amgen's European patent application EP3801681A1 on March 25, 2026, covering modular fluid path assemblies for drug delivery devices. The invention relates to fluid path configurations designed to enhance drug delivery performance and reliability. The patent names eight inventors and is classified under A61M 5/142, with designation extending to 27 European states including AL, AT, BE, DE, ES, FI, FR, GB, GR, IT, NL, PL, and SE.\n\nPharmaceutical and medical device companies developing drug delivery systems should review this patent publication for freedom-to-operate analysis. Competitors in the modular drug delivery device space should evaluate whether their products may fall within the scope of the claimed invention. This publication serves as prior art as of March 25, 2026, and may impact pending or future patent applications in this technology area. No immediate compliance action is required, but legal teams should monitor this patent through the examination process.